In episode 10 of our COVID19 Road to a vaccine series, our host, Nigel Crawford, speaks with Professors Paul Young and Trent Munro to discuss the University of Queensland (UQ) COVID-19 vaccine candidate. UQ and CEPI (the Coalition for Epidemic Preparedness and Innovation) have partnered with CSL (Seqirus) to advance their novel molecular clamp technology to develop their vaccine for COVID-19. This vaccine has recently progressed to Phase 1 clinical trials. In this episode they discuss:
- The University of Queensland COVID19 vaccine development process
- The involvement of CEPI in their trial
- The use of a molecular clamp platform in the development of their protein SARS-CoV-2 vaccine
- Results of their preclinical trials
- Their partnership with CSL/Seqirus and the use of the MF59 adjuvant
- The timeline of their clinical trials and the upcoming steps
Links:
- CEPI partners with University of Queensland to create rapid response vaccines
- Dosing begins in the first human trial of UQ’s COVID-19 vaccine
- The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate
Listen to the episode here: